Physician Sentiment on TRODELVY®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-13. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT05382299

What do oncologists think of the ASCENT-03 trial (TRODELVY®)?

ASCENT-03 — 1L metastatic TNBC, not candidates for PD-(L)1 inhibitors (monotherapy)

FDA APPROVED · Jun 2026FDA-approved June 2026 as monotherapy for first-line metastatic triple-negative breast cancer in patients who are not candidates for PD-(L)1 inhibitors.

Physicians are broadly favorable, with real nuance on ASCENT-03: 23% of 26 verified physician voices positive, 8% nuanced (praising the result while flagging a caveat), 69% neutral, 0% critical.

23%

69%

Positive 23% Nuanced 8% Neutral 69% Critical 0%

Denominator: 26 distinct verified physician voices across 58 oncologist posts, 2025-05-23 to 2026-06-02. Sponsor: Gilead Sciences

See full ASCENT-03 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05382299

FDA approval (June 24, 2026): sacituzumab govitecan-hziy for unresectable locally advanced or metastatic triple-negative breast cancer previously untreated and not candidates for PD-(L)1 inhibitors (based on ASCENT-03, NCT05382299).

Physician voices — verbatim

Representative positive voice

ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs after progression on 1L SG (PFS 9 mo)?

Paolo Tarantino

@PTarantinoMD

Representative nuanced voice

Actually dato is a great drug but the comment above isn’t really true. >80% on ascent x’d over from control to SG. No one x’d over in tropion. We can’t encourage crossover & opportunity for our patients participating in trials on the one hand then ding them for it! @OncoAlert

Hope Rugo

@hoperugo

Full physician voice list (26)

Physician	Comment (verbatim)	Sentiment	Impressions
Paolo Tarantino @PTarantinoMD	ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs a…	Positive	22,326
Hope Rugo @hoperugo	Actually dato is a great drug but the comment above isn’t really true. >80% on ascent x’d over from control to SG. No one x’d over in tropion. We can’t encourage crossover & opportunity for our patients participating in trials on the one ha…	Nuanced	5,853
Oncology Brothers @OncBrothers	Day 3 & 4 #ASCO26 highlights: 1. #evERA: Giredestrant in mHR+ BC 2. #ASCENT03/04: Saci 1L mTNBC 3. #CIRCULATE: ctDNA in CRC 4. #EPISODE3: Adj Aspirin in CRC 5. #EMERALD3: STRIDE + TACE + Len in HCC 6. #DeLLphi304: Tarla in SCLC @A…	Neutral	5,815
Dr Sarah Sammons @drsarahsam	I think choice can be guided by the safety profile and infusion schedule. Personally the ORR of Dato-Dxd was quite higher in a higher risk population.	Neutral	5,716
Dr Amol Akhade @SuyogCancer	📢 ASCENT-03 delivers for Trodelvy in 1L mTNBC! ❤ Trodelvy (sacituzumab govitecan) shows a statistically significant & clinically meaningful PFS benefit vs chemo ❌ In a tough group: PD-L1–negative or IO-ineligible mTNBC 🧬 First ADC to poten…	Neutral	4,905
Matteo Lambertini, MD PhD @matteolambe	Wow…what a fantastic discussion at #ESMO25 by Dr. Garrido-Castro from @DFCI_BreastOnc 🙌🤩 first-line therapy in advanced triple-negative #BreastCancer not eligible for IO has finally changed !!! @OncoAlert @myESMO #bcsm	Positive	3,728
Mali Barbi, MD MSc \| Breast & Gyn Oncologist @DrBarbiOnc	#ASCO26 Abstracts 1001 and 1002. Both follow up on trials that already changed frontline #mTNBC in 2025. #ASCENT03 (Abstract 1001): #sacituzumab_govitecan established at ASCO 2025. Now, does the PFS benefit hold beyond first progression? PF…	Neutral	3,393
Yakup Ergün @dr_yakupergun	#ASCO26 ASCENT-03 PFS2 analysis PFS2 difference was 4.2 mo✅️ This is notable because 82% of patients in the chemo arm received SG as subsequent therapy. Despite this crossover, earlier SG still maintained a PFS2 advantage. This streng…	Neutral	2,372
tatsunori_shimoi 下井辰徳 @shimoi_oncology	#ASCO26 ASCO 2026 Breast Cancer (Metastatic) Rapid Oral session May 31, 11:30-13:00PM 1. ASCENT-04 biomarker subgroup analysis 2. ASCENT-03 biomarker subgroup analysis 3. 食事へのアクセスと貧困がMBCのゲノム異常への影響があるか？ 4. evERA（giredestrant + everolimus）のP…	Neutral	2,187
Dr Rishabh Jain @DrRishabhOnco	#ASCO26 🎗️ Sacituzumab govitecan (SG) keeps extending its lead in 1L metastatic TNBC. 📈 ASCENT-03 showed improved PFS2 despite heavy crossover to SG after progression. 🔄 📌 mTNBC not eligible for PD-(L)1 inhibitors 📌 1L SG vs physician’s c…	Neutral	2,156
Erika Hamilton, MD, FASCO @ErikaHamilton9	presents #ASCENT03 saci vs. TPC chemo in 1L TNBC that is PDL1 neg (~65% of pts w/ TNBC) 1/3 pts. de novo Taxane picked 55%, carbo/gem 45% 6.9 mo TPC vs. 9.7 months w/ SG l, HR 0.62 ORR 🟰 DOR longer w/ SG #ESMO25 #ESMOAmbassadors	Neutral	1,590
Rebecca Shatsky, MD @Dr_RShatsky	This! Trop2 ADCs should be considered the new standard of care in 1L mTNBC. In the post Keynote 522 era, using the Keynote 355 data makes no sense. These patients have already seen those drugs. Keynote 355 is really obsolete at this point. …	Positive	1,483
Kazuki Nozawa, MD @kazuki_nozawa	PFS2 in Metastatic Breast Cancer: What Does It Really Mean? Great review!! (1) PFS2 lacks a standardized definition and varies across trials, making cross-study comparisons difficult. (2) In studies such as ASCENT-03/04 and TROPION-Breast…	Neutral	1,280
Sarah Premji, MD @SPremji7866	#ASCO26 this morning we heard about several subsequent measures in ASCENT03, ASCENT04 and TB02 including PFS-2, great to see this data, however Meredith Regan reviews that significant caution should be used in interpretation of PFS-2, notab…	Nuanced	860
Aya Mohamed \| MSc, MD 🎗 @Dr_Oncologista	#ASCO26 Practice-Changing: The ASCENT-03 Trial, presented by @stolaney1 establishes Sacituzumab Govitecan as the new first line standard of care for PD-(L)1-ineligible metastatic TNBC, delivering superior and durable disease control beyo…	Positive	492
Sara Soliman, MD @sara_soliman7	ASCENT 03 binaries analysis 🚨 SG ➡️ improved PFS > chemo as 1L in TNBC 📌Benefit observed in variable TROP2 expression, BRCA mutation and HER2 expression subgroups!! 🔪The bystander effect with SG—benefit in low TROP2 expression! @OncoA…	Neutral	413
Icro Meattini @Icro_Meattini	ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan vs chemotherapy in participants with previously untreated advanced triple-negative #breastcancer who are not candidates for PD-(L)1 inhibitors Carlos H. Barrios #ASCO26 …	Neutral	412
VIRGINIA KAKLAMANI @VKaklamani	Agree. 2 adcs that have improved activity compared with chemo in 1st line tnbc. Pick your favorite and use it as soon as it gets approved instead of chemo. For pdl1 pos use sg with pembro.	Neutral	373
Armando Orlandi @ArmandOrlandi	🔬 Methods Corner 🌊 from #ASCO26 A quick stats cheer for the PFS2 crowd 🏄🏻‍♂️👏 ✅ ASCENT-03 & ASCENT-04: PFS2 P-values correctly flagged as nominal — exploratory endpoints, no alpha spent. ✅ TROPION-Breast02: equally rigorous — PFS2, TFST …	Positive	305
Elisa Agostinetto @ElisaAgostinett	At #ASCO26 metastatic #breastcancer session, @stolaney1 presents results on the PFS2 from the ASCENT-03 trial PFS2 was longer in the SG arm vs CT arm, despite high rate of tx crossover, with most pts in the CT arm receiving SG after progres…	Neutral	239
Abi Siva MD @AbiSivaMD	ASCENT-03: Even with 82% crossover to SG in the chemo arm, 1L SG maintained a PFS2 benefit. PFS2: 18.2 vs 14.0 months (HR 0.70) An important reminder that when effective therapies exist, PFS2 can provide valuable insight into the impact o…	Neutral	235
Jennifer Litton @JenniferLitton	Absolutely agree Hope. Crossover design should be encouraged here, The differentiators then we are left with inclusion/exclusion criteria and side effects	Positive	188
Gaia Griguolo @GaiaGriguolo	In ASCENT-03 SG significantly improved PFS2 and time to further subsequent therapy as compared to chemo in untreated metastatic TNBC not candidate for ICI (median PFS2 18.2 Vs 14.0 mos) Despite crossover✅ @OncoAlert #asco26	Neutral	142
Naoto T Ueno, MD, PhD @teamoncology	Both ASCENT-04 and ASCENT-03 efficacy is lbiomarker independent. Is this surprising? Not really. We have seen a similar pattern across the DESTINY-Breast studies, where no biomarker has been statistically meaningful enough to clearly define…	Neutral	79
Santhosh Ambika @RenoHemonc	Dato > SG when it comes to patient tolerance..	Neutral	39
Mustafa Özdoğan, MD @ozdogan_md	Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next…	Neutral	0

See full ASCENT-03 conference coverage & trial data →

Trial 2 · NCT05382286

What do oncologists think of the ASCENT-04 trial (TRODELVY®)?

ASCENT-04 — 1L PD-L1-positive (CPS ≥ 10) metastatic TNBC (with pembrolizumab)

FDA APPROVED · Jun 2026FDA-approved June 2026 in combination with pembrolizumab (Keytruda, Merck) for first-line PD-L1-positive (CPS ≥ 10) metastatic triple-negative breast cancer. The sacituzumab-govitecan-plus-pembrolizumab combination is FDA-approved only in this PD-L1-positive setting.

Physicians are broadly favorable, with real nuance on ASCENT-04: 36% of 45 verified physician voices positive, 15% nuanced (praising the result while flagging a caveat), 42% neutral, 7% critical.

36%

15%

42%

Positive 36% Nuanced 15% Neutral 42% Critical 7%

Denominator: 45 distinct verified physician voices across 90 oncologist posts, 2025-04-21 to 2026-06-02. Sponsor: Gilead Sciences

See full ASCENT-04 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05382286

FDA approval (June 24, 2026): sacituzumab govitecan-hziy with pembrolizumab for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥ 10) (based on ASCENT-04 / KEYNOTE-D19, NCT05382286).

Physician voices — verbatim

Representative positive voice

Paolo Tarantino

@PTarantinoMD

Representative nuanced voice

First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️ Crossover 80% Sacituzumab Offered! Very few patients with prior IO, few who relapsed within 6-12 months. OS looks similar but early days. #bcsm great job @stolaney1 !!

Dr Sarah Sammons

@drsarahsam

Representative critical voice

T - Dxd followed by chemo followed by Dato Dxd Back to back trop2 payload ADC outcomes ain’t great per RWE

Santhosh Ambika

@RenoHemonc

Full physician voice list (45)

Physician	Comment (verbatim)	Sentiment	Impressions
Paolo Tarantino @PTarantinoMD	ASCENT-03 & -04 are positive: we may soon have the option of 1L SG (+/- pembro) for mTNBC. If TB02 is positive, we may also soon have Dato-DXd. ❓How will you treat a 50yo patient with TNBC (PD-L1-, IHC 1+) de novo metastatic to the lungs a…	Positive	22,326
Sara Tolaney @stolaney1	A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new …	Positive	12,987
Harold J. Burstein, MD, PhD, FASCO @DrHBurstein	Thematic take on @ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually g…	Neutral	8,348
Dr Rishabh Jain @DrRishabhOnco	#ASCO26 🔥 ASCENT-04 biomarker analysis strengthens the 1L mTNBC story: SG + pembrolizumab beat chemo + pembrolizumab across biomarker groups. Key signal: 🧬 Trop-2 benefit in all quartiles Strongest in higher Trop-2: Q3 HR 0.46 Q4 HR 0.57…	Positive	6,966
Tom Powles @tompowles1	Two ADC/PD1 combinations show +ve efficacy in 1st line breast cancer. ASCENT-04: sacituzumab/pembro vs TPC/pembro in mTNBC =⬆️ PFS & DESTINY-B09 TDXD/Pembro vs THP in HER2+ ⬆️PFS. Topo-1:TROP2/PD1 ADC/IO combos struggled in bladder cancer. …	Positive	6,778
Dr Sarah Sammons @drsarahsam	First-line Sacituzumab + Pembrolizumab improves PFS in 1st Line TNBC. 🚨🔔‼️ Crossover 80% Sacituzumab Offered! Very few patients with prior IO, few who relapsed within 6-12 months. OS looks similar but early days. #bcsm great job @sto…	Nuanced	6,720
Giampaolo Bianchini @BianchiniGP	🔥 #ASCO25 Sacituzumab Govitecan + Pembro could be new standard of care in PD-L1+, 1st line TNBC (ASCENT 4) (@stolaney1) ⬆️ PFS HR = 0.65 11.2 vs 7.8 months ⬇️ early PD (1/3) ⬆️ CR and DoR Only 5% received ICI in early setting 👉 Which is …	Positive	4,883
Icro Meattini @Icro_Meattini	ASCENT-04 - sacituzumab govitecan plus pembrolizumab as a new standard for #BreastCancer with previously untreated PDL1+ TNBC #ASCO25 @stolaney1 @OncoAlert #OncoAlert	Positive	3,559
Elisa Agostinetto @ElisaAgostinett	At #ESMO25 mini-oral session on MBC, @E_de_Azambuja presents PROs of ASCENT-04 SG + pembro maintained overall QoL, patients reported reduction in symptoms burden and improved function in several domains @OncoAlert	Neutral	3,529
Dr Amol Akhade @SuyogCancer	Today is day of press release. Sacituzumab govitecan plus pembrolizumab shows PFS benefit over chemo plus Pembrolizumab in metastatic TNBC with CPS > 10 . Ascent 04 trial. @OncoAlert @OncLive #BCSM looking forward to Magnitude of benifit…	Neutral	2,877
Dra. María Natalia Gandur Quiroga @nataliagandur	💫🌟🚨 Top 10 #BreastCancer abstracts for #ASCO26 — selected by our leads and finalized via a Delphi voting process 🗳️🔬 1️⃣ 500 — OPTIMA 2️⃣ LBA1006 — PERSEVERA BC 3️⃣ 507 — KEYNOTE-522 final analysis 4️⃣ LBA1007 — SERENA-6 5️⃣ 502 — LIDERA B…	Neutral	2,803
Evandro de Azambuja, MD, PhD @E_de_Azambuja	Looking forward to this important milestone for #patients with #TNBC nad PDL1+ tumours: Sacitizumab + Pembrolizumab as 1st line therapy! @GileadSciences	Positive	2,597
Stephanie Graff, MD, FACP, FASCO @DrSGraff	ASCENT-04 show sustained physical function and predictable side effects (diarrhea, nausea), reduced pain with Sacituzumab —@E_de_Azambuja #ESMO25 @OncoAlert	Neutral	2,541
Kristina Jankovic, MD @JankovicK	My 🔝 PICKS from The OncoAlert🚨 Weekly Round-Up (Apr 18–24, 2025): ✨ 🆙date on DESTINY-Breast09 ✨ 🆙date on ASCENT-04 ✨ Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients Register at https://t.co/T…	Neutral	2,268
Hope Rugo @hoperugo	And ASCENT 04 - first line SG with pembro beats chemo plus pembro. #ASCO25	Neutral	2,208
tatsunori_shimoi 下井辰徳 @shimoi_oncology	#ASCO26 ASCO 2026 Breast Cancer (Metastatic) Rapid Oral session May 31, 11:30-13:00PM 1. ASCENT-04 biomarker subgroup analysis 2. ASCENT-03 biomarker subgroup analysis 3. 食事へのアクセスと貧困がMBCのゲノム異常への影響があるか？ 4. evERA（giredestrant + everolimus）のP…	Neutral	2,187
Erika Hamilton, MD @ErikaHamilton9	Big day in #bcsm, sacituzumab govitecan with pembro beats chemo+ pembro in 1L TNBC that is PDL1 +! The #ADCs are moving up!	Positive	1,925
Luca Arecco, MD @Lucarecco	Super @JulesBordet and @myESMO mentor @E_de_Azambuja presented QoL results from the ASCENT-04 trial at #ESMO25. SG+Pembro maintained QoL and reduced symptom burden, a key finding in an era where novel agents may be more toxic than SOC.	Nuanced	1,646
Komal Jhaveri @jhaveri_komal	Great news! Looking forward to the data ADC sequencing becoming more important a question!	Positive	1,633
Gaia Griguolo @GaiaGriguolo	ASCENT-04 presented by @stolaney1 #ASCO25 SG+pembro vs CT+pembro in PD-L1+ TNBC 1st line Significant PFS benefit 11.2 vs 7.8 mos Immature OS Is combining in first-line the best choice? @OncoAlert	Nuanced	1,622
Guilherme Nader Marta @GuiNaderMarta	ASCENT-04 presented by @stolaney1 at #ASCO25 SG + pembro vs chemo + pembro in PD-L1+ adv TNBC PFS: HR 0.65 (0.51–0.84), P = .0009 ORR 59.7% vs 53.2% DOR 16.5 vs 9.2 mo G≥3 AEs 71% vs 70% Dose red: 35% vs 44% ‼️ New 1st line option f…	Positive	1,613
Oncology Brothers @OncBrothers	2. ASCENT-03 & 04: Ph III, Sacituzumab +/- IO vs. Chemo 1L mTNBC - Improved PFS in all subgroups (regardless of BRCA, Her2 low, or TROP2 expression) - We now have 2 options in 1L TNBC: Saci +/- IO or DatoDXd 3/7 https://t.co/MtAhWEqEva	Neutral	1,461
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌 Patient-reported outcomes with sacituzumab govitecan + pembro vs chemo + pembro in pts with previously untreated PD-L1+ mTNBC in the phase III ASCENT-04 trial @E_de_Azambuja Mini oral Session #ESMO25 @OncoAlert #OncoAlertAF	Neutral	1,345
Katy Beckermann @katy_beckermann	EV+pembro is now first-line standard after EV-302 (updated at #ASCO26). 6 urothelial trials at ASCO 2026 are already testing what follows, 3 in Phase 3. 📈 Two TROP-2 strategies: Dato-DXd post-EV/pembro (TROPION-Uro03) + SG+pembro in ICI-re…	Neutral	1,337
VIRGINIA KAKLAMANI @VKaklamani	Robust benefit of SG+pembro in first line tnbc. Still don’t know what to do post kn522 since very few such patients included but this should be a new soc. @stolaney1 #ASCO2025	Nuanced	1,043
Matteo Lambertini, MD PhD @matteolambe	Very much awaited data from #ASCENT04 trial presented at #ASCO25 by the great @stolaney1 from @DanaFarber showing improved PFS with the combination of #sacituzumabGovitecan + #pembrolizumab as first-line therapy in patients with PDL1+ tripl…	Neutral	985
Yakup Ergün @dr_yakupergun	#ASCO26 ASCENT-04 PFS2 In 1L PD-L1+ mTNBC, SG + pembrolizumab maintained its PFS2 advantage over chemo + pembrolizumab PFS2: NR vs 21.0 mos HR 0.67 In the control arm, 77% of patients received SG in the subsequent line; despite this…	Neutral	954
MV Chandrakanth @ChandrakanthMv	ASCENT-04 (Tolaney et al., ASCO 2026) Trop-2 may enrich benefit magnitude—but no biomarker subgroup clearly lost benefit. SG + pembrolizumab demonstrated consistent activity across evaluated Trop-2, BRCA, and HER2-defined subgroups in PD-…	Nuanced	914
Sarah Premji, MD @SPremji7866	#ASCO26 this morning we heard about several subsequent measures in ASCENT03, ASCENT04 and TB02 including PFS-2, great to see this data, however Meredith Regan reviews that significant caution should be used in interpretation of PFS-2, notab…	Nuanced	860
Elvina Almuradova @Dr_ElvinaA	ASCENT-04/KEYNOTE-D19 (NEJM, Jan 22, 2026): SG + pembrolizumab improves PFS in 1L PD-L1+ advanced/metastatic TNBC! 👍mPFS 11.2 vs 7.8 mo \| HR 0.65 👍 mDoR 16.5 vs 9.2 months OS data are still immature, and crossover may impact OS separation…	Nuanced	746
Yara Abdou, MD, MSCR @YAbdouMD	#ASCENT04: PFS benefit with SG + pembro consistent across biomarker subgroups — including TROP2 expression quartiles, BRCA status, and HER2 status. Biomarkers that truly refine patient selection beyond broad subgroup labels continues to be…	Positive	618
Antonio Giordano, MD PhD @antgiorda	🔔Practice change alert for breast cancer physicians #bcsm ‼️Schedule your K522 and ascent-04 pts in the morning‼️ Randomized clinical trial shows improved OS…HR 0.45, for lung ca patients receiving NACT with immunotherapy in the morning #A…	Positive	519
Aya Mohamed \| MSc, MD 🎗 @Dr_Oncologista	Landmark Advance: ASCENT-04 Redefines First Line Therapy in PD-L1+ mTNBC with Sacituzumab Govitecan + Pembrolizumab @OncoAlert #ASCO26 #BreastCancer #bcsm	Neutral	499
Eleonora Teplinsky, MD, FASCO @drteplinsky	We talk about SERENA-6, ASCENT-04, DESTINY-Breast09 - what they show, limitations, next steps etc! #ASCO25	Neutral	458
Nicole Casasanta, MD @ncasasanta	📉PFS2 in MBC ✨Impressive discussion by Meredith Regan on PFS2 🔹in metastatic TNBC ASCENT03, TROPION Breast02, & ASCENT04 all reporting improvements in PFS2 for experimental groups reaching SG or Dato-DXd in 1L 🔹PFS2 definition different and…	Positive	453
Aydah AlAwadhi, MD 🇦🇪 @Aydah_AlAwadhi	#ASCO26 ASCENT-04: • SG + pembrolizumab improved PFS vs chemo + pembrolizumab in PD-L1+ mTNBC. PFS Benefit seen across Trop-2, tBRCA, and HER2-low/IHC0 subgroups @OncoAlert #ASCO2026 #bcsm	Neutral	427
Santhosh Ambika @RenoHemonc	T - Dxd followed by chemo followed by Dato Dxd Back to back trop2 payload ADC outcomes ain’t great per RWE	Negative	389
Romualdo Barroso, MD PhD @DrRBarroso	Another one for Dr @stolaney1 She will be presenting the primary results of ASCENT-04 at ASCO 2025 - on May 31st at HALL B1 in the afternoon @DFCI_BreastOnc @DanaFarber @ASCO #tnbc #immunotherapy #sacituzumabgovitecan #ASCO25	Neutral	351
Armando Orlandi @ArmandOrlandi	🔬 Methods Corner 🌊 from #ASCO26 A quick stats cheer for the PFS2 crowd 🏄🏻‍♂️👏 ✅ ASCENT-03 & ASCENT-04: PFS2 P-values correctly flagged as nominal — exploratory endpoints, no alpha spent. ✅ TROPION-Breast02: equally rigorous — PFS2, TFST …	Positive	305
Kazuki Nozawa, MD @kazuki_nozawa	ASCENT-04 Biomarker Analysis #ASCO26 @stolaney1 SG + pembrolizumab demonstrated superior PFS over chemo + pembrolizumab in previously untreated PD-L1+ metastatic TNBC. Consistent benefit observed across: All Trop-2 expression quartiles …	Neutral	290
Bijoy Telivala @BijoyTelivala	Press releases are for Wall Street only For Main street ( doctors, patients etc ) we should wait for the real data To the CMO - This drug has significant toxicity... Clinical meaningful lies in the eye of the beholder ( when no numbers ar…	Negative	179
Abhenil Mittal @abhenilmittal	Hate these press releases. Keep you on the edge without actually giving any useful info. Ofcourse PFS is better, need to see the data to make any decisions.	Negative	119
Corey Speers @cwspeers	2️⃣ LBA109 – ASCENT-04 / KEYNOTE-D19 📌 SG + pembrolizumab in PD-L1+ mTNBC ➡️ Early data suggests improved response vs SOC—could shape future 1L immunotherapy in TNBC. #TNBC #immunotherapy	Positive	109
Naoto T Ueno, MD, PhD @teamoncology	Both ASCENT-04 and ASCENT-03 efficacy is lbiomarker independent. Is this surprising? Not really. We have seen a similar pattern across the DESTINY-Breast studies, where no biomarker has been statistically meaningful enough to clearly define…	Neutral	79
Laila Agrawal, MD @LailaAgrawalMD	ASCENT-04 - Improved PFS with saci + pembro vs chemo + pembro 11.2 mo vs 7.8 in PDL1+ MBC 1st line. Improved ORR and duration of response. Do you think this is immediately practice changing? Will insurance pay💰? #ASCO25	Positive	76

See full ASCENT-04 conference coverage & trial data →

Trial 3 · NCT04448886

What do oncologists think of the SACI-IO HR+ trial (TRODELVY®)?

SACI-IO HR+ — HR+/HER2- metastatic breast cancer (SG ± pembrolizumab) — INVESTIGATIONAL

INVESTIGATIONALInvestigational. SACI-IO HR+ studied sacituzumab govitecan ± pembrolizumab in HR+/HER2- metastatic breast cancer; this combination is not FDA-approved, and the trial did not reach statistical significance for its primary progression-free-survival endpoint in the overall population.

Physicians are genuinely mixed on SACI-IO HR+: 20% of 15 verified physician voices positive, 40% nuanced (praising the result while flagging a caveat), 27% neutral, 13% critical.

20%

40%

27%

13%

Positive 20% Nuanced 40% Neutral 27% Critical 13%

Denominator: 15 distinct verified physician voices across 27 oncologist posts, 2024-06-01 to 2026-05-08. Sponsor: Dana-Farber Cancer Institute (investigator-initiated); PI Ana Garrido-Castro

See full SACI-IO HR+ conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04448886

Physician voices — verbatim

Representative positive voice

SACI-IO HR+ trial results presented by Ana Garrido-Castro from @DFCI_BreastOnc The addition of pembrolizumab to sacituzumab govitecan did not improve PFS compared to SG alone in pts w/ ER+ disease Interesting signal seen among pts with PD-L1+ disease @OncoAlert

Guilherme Nader Marta

@GuiNaderMarta

Representative nuanced voice

#ASCO24 SACI-IO: SG w/wo Pembro in pts with metastatic HR+/HER2-BC 🔍≥1 prior ET and 0-1 ChT for MBC PFS➡️8.1 vs 6.2 mo (HR 0.76 but NS) OS➡️18.5 vs 17.9 mo (immature) Addition of Pembro to SG showed a non-significant trend toward improved PFS @OncoAlert

Yakup Ergün

@dr_yakupergun

Representative critical voice

Dr. Garrido Castro presents #SACI-IO-HR+ No benefit of adding pembro to saci in HR+ MBC Trend toward some benefit among those with PD-L1+ disease but small #s #ESMOBreast26 #bcsm

Erika Hamilton, MD, FASCO

@ErikaHamilton9

Full physician voice list (15)

Physician	Comment (verbatim)	Sentiment	Impressions
Stephanie Graff, MD, FACP, FASCO @DrSGraff	SACI-IO HR+ in pts w/PDL1 unselected HR+ MBC, pembrolizumab + sacituzumab govitecan (SG) did not improve mPFS vs SG alone (8.1 vs 6.2 months, HR 0.81, p=0.37). a non-significant trend seen among patients w/ PD-L1+ (CPS ≥1) Larger trials o…	Neutral	3,307
Hope Rugo @hoperugo	Ana garrida-castro presents Saci-IO in HR+ MBC. Intriguing trend towards improved PFS and OS in CPS+ disease with SG Pembo vs SG, underpowered for significance. HR neg study ongoing! #ASCO24 @OncoAlert	Neutral	2,998
Yakup Ergün @dr_yakupergun	#ASCO24 SACI-IO: SG w/wo Pembro in pts with metastatic HR+/HER2-BC 🔍≥1 prior ET and 0-1 ChT for MBC PFS➡️8.1 vs 6.2 mo (HR 0.76 but NS) OS➡️18.5 vs 17.9 mo (immature) Addition of Pembro to SG showed a non-significant trend toward…	Nuanced	2,767
Paolo Tarantino @PTarantinoMD	Ana Garrido-Castro from @DFCI_BreastOnc presents the results of SACI-IO HR+ investigator-initiated trial. Adding pembro to SG did not improve PFS in unselected pts with HR+ MBC (8.1 vs 6.2 mo, HR 0.81), although an intriguing trend in PFS a…	Nuanced	2,748
Guilherme Nader Marta @GuiNaderMarta	SACI-IO HR+ trial results presented by Ana Garrido-Castro from @DFCI_BreastOnc The addition of pembrolizumab to sacituzumab govitecan did not improve PFS compared to SG alone in pts w/ ER+ disease Interesting signal seen among pts with P…	Positive	1,024
Dr Rishabh Jain @DrRishabhOnco	#ESMOBreast26 SACI-IO HR+ final results: Does pembrolizumab add benefit to sacituzumab govitecan in HR+/HER2- mBC? 🧬 PD-L1+ subgroup (CPS ≥1; n=39): 📈 mPFS: 9.7 vs 5.6 mo 📈 mOS: 24.3 vs 17.7 mo But: ⚠️ PFS p=0.11 ⚠️ OS p=0.34 🩺 No new …	Nuanced	505
Kazuki Nozawa, MD @kazuki_nozawa	#ESMOBreast26 Final results of phase II SACI-IO HR+ trial Adding pembrolizumab to SG did not significantly improve PFS or OS in unselected HR+/HER2− metastatic breast cancer. However, exploratory analyses suggested clinically meaningful…	Nuanced	344
Armando Orlandi @ArmandOrlandi	Cowabunga! Riding Breast Cancer's Biggest Data’s Wave 🏄🏻‍♂️🌊🤙🏻from #ASCO24 SACI-IO - HR+\HER2- mBC phase II- +Pembro no significant difference in PFS vs SACI alone. @OncoAlert @OncBrothers @VJOncology @OncLive @ASCO @Oncoinfo	Positive	266
Laila Agrawal, MD @LailaAgrawalMD	SACI-IO HR+ #ASCO24 Adding pembro to Sacituzumab (SG) did not improve PFS, but non-significant difference seen based on PDL1 status Trial was changed to include PDL1 negative based on low accrual 🧠Maybe using AI can improve clinical tria…	Nuanced	265
Elvina Almuradova @Dr_ElvinaA	Key data from the SACI-IO HR+ study (ESMO): In metastatic HR+/HER2- breast cancer, adding Pembrolizumab to Sacituzumab Govitecan (SG) showed: • Overall Population: No significant improvement in PFS or OS. • PD-L1+ Subgroup (CPS ≥1): Clinica…	Neutral	250
Aya Mohamed, MD MSc 🎗 @Dr_Oncologista	📌 A great study that explains: SACI-IO HR+ At a follow-up of 12.5 months, there was no difference in OS with Sacituzumab Govitecan + Pembrolizumab compared with Sacituzumab Govitecan alone in patients with HR+/HER2- metastatic #breastcanc…	Positive	201
Abi Siva MD @AbiSivaMD	SACI-IO HR+: Adding pembrolizumab to SG did not improve PFS or OS overall in HR+ MBC, but a promising signal was seen in the PD-L1+ subgroup (CPS ≥1). More exploration needed. #ESMOBreast26	Nuanced	0
Erika Hamilton, MD, FASCO @ErikaHamilton9	Dr. Garrido Castro presents #SACI-IO-HR+ No benefit of adding pembro to saci in HR+ MBC Trend toward some benefit among those with PD-L1+ disease but small #s #ESMOBreast26 #bcsm	Negative	0
Dr Amol Akhade @SuyogCancer	Can we add pembrolizumab to SG for metastatic HR postive Her2 negative MBC? Not much benifit of PFS . 8.4 months vs 6.2 months . Not much useful strategy. @ASCO @OncoAlert #asco24 @Larvol	Negative	0
Nirmal Raut @oncologician	Ana Christina Garrido Castro from DANA FARBER on sequencing agents in metastatic breast cancer #ASCO24	Neutral	0

See full SACI-IO HR+ conference coverage & trial data →

Trial 4 · NCT05840211

What do oncologists think of the ASCENT-07 trial (TRODELVY®)?

ASCENT-07 — 1L chemo in HR+/HER2- MBC after endocrine therapy — INVESTIGATIONAL (did not meet primary endpoint)

INVESTIGATIONAL · DID NOT MEET PRIMARY ENDPOINTInvestigational in this setting. ASCENT-07 tested first-line sacituzumab govitecan versus chemotherapy in HR+/HER2- metastatic breast cancer after endocrine therapy and did NOT meet its primary progression-free-survival endpoint (SABCS 2025). Trodelvy's HR+/HER2- approval remains based on the later-line TROPiCS-02 trial.

Physicians are skeptical on ASCENT-07: 0% of 14 verified physician voices positive, 7% nuanced (praising the result while flagging a caveat), 57% neutral, 36% critical.

57%

36%

Positive 0% Nuanced 7% Neutral 57% Critical 36%

Denominator: 14 distinct verified physician voices across 25 oncologist posts, 2025-11-07 to 2025-12-11. Sponsor: Gilead Sciences; PI Komal Jhaveri

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT05840211

Physician voices — verbatim

Representative nuanced voice

#SABCS2025 Komal Jhaveri presents our data from Ascent 07. No difference in PFS first line chemo for HR+ MBC post ET by BICR but high censoring as inv changed therapy due to new lesions not called by BICR. Trend in OS interesting. Role in HER20 remains. @OncoAlert

Hope Rugo

@hoperugo

Representative critical voice

ASCENT-07 fails to show benefit of saci over chemo in 1L cytotoxic HR+ #bcsm. Surprising, we have PFS and OS benefit in the next line. Only thing I can think of is it lost to capecitabine here. Cape is a good drug for HR+.

Erika Hamilton, MD, FASCO

@ErikaHamilton9

Full physician voice list (14)

Physician	Comment (verbatim)	Sentiment	Impressions
Paolo Tarantino @PTarantinoMD	Negative press release from ASCENT-07: in pts with ER+ MBC refractory to endocrine treatment, first-line SG did not improve PFS compared with chemo. In this setting, T-DXd outperformed chemo (DB-06) and a phase 3 is ongoing with Sac-TMT +/-…	Neutral	17,466
Erika Hamilton, MD, FASCO @ErikaHamilton9	ASCENT-07 fails to show benefit of saci over chemo in 1L cytotoxic HR+ #bcsm. Surprising, we have PFS and OS benefit in the next line. Only thing I can think of is it lost to capecitabine here. Cape is a good drug for HR+.	Negative	11,715
Yakup Ergün @dr_yakupergun	#SABCS25 Beyond the trials we expect to read out positively, I think one of the most debated studies will be ASCENT-07. A drug that improved both PFS and OS in TROPiCS-02 failed to show a PFS benefit in an earlier, more chemo-sensitive set…	Negative	8,846
Sara Tolaney @stolaney1	ASCENT-07: sacituzumab govitecan vs TPC as 1L chemo in HR+ MBC by @jhaveri_komal median f/u 15.4 mo n=690 TPC (43% cape, 57% taxane) PFS by BICR 8.3 mo vs 8.3 mo, HR 0.85,p=.13 Inv PFS 8.4 vs 6.4 (HR 0.78) OS HR 0.72 (61% in TPC recv'd…	Neutral	6,350
Hope Rugo @hoperugo	#SABCS2025 Komal Jhaveri presents our data from Ascent 07. No difference in PFS first line chemo for HR+ MBC post ET by BICR but high censoring as inv changed therapy due to new lesions not called by BICR. Trend in OS interesting. Role in H…	Nuanced	6,173
Dr Sarah Sammons @drsarahsam	TDXd remains optimal ADC for most patients with ER+ MBC 10% HER2 null, chemotherapy first line still standard. Then Dato-DXd or Saci.	Neutral	3,819
Luca Arecco, MD @Lucarecco	GS1-09 – #SABCS25 ASCENT-07 (SG vs CT after ET in HR+/HER2– mBC) did not meet its primary endpoint, with similar PFS between SG and CT. ORR similar between treatment arms @OncoAlert @SABCSSanAntonio	Negative	901
Oncology Brothers @OncBrothers	3. #ASCENT07: PhIII, #Sacituzumab vs. treatment of physician’s choice in HR+/HER2– locally advanced or mBC post-ET: - No improvement in mPFS w/ Saci when compared to Chemo - Saci approval/sequence based off #TROPiCS02 in later lines stil…	Negative	852
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌GS1: ✨Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2-(IHC 0, 1+, 2+/ISH-) metastatic breast cancer: Primary results from ASCENT-07 Presented by @jhaveri_komal #SABCS25 @OncoAlert #OncoAlertAF @M…	Neutral	841
Elvina Almuradova @Dr_ElvinaA	In the ASCENT-07 trial, Trodelvy after endocrine therapy did not improve PFS vs chemotherapy in HR+/HER2- metastatic breast cancer. @Larvol @oncodaily @OncoAlert #breastcancer	Neutral	725
tatsunori_shimoi 下井辰徳 @shimoi_oncology	#SABCS25 ASCENT-07 GS1-10 Day 2: December 10, 2025 Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07 Komal L. Jhaveri,…	Neutral	709
Dr Amol Akhade @SuyogCancer	Negative trials are important. Any explanation why it did not work 🤔 in this setting ? @dr_yakupergun @drsarahsam @SABCSSanAntonio #SABCS2025	Negative	615
Santhosh Ambika @RenoHemonc	T- DXd the king for ER+ and her2ultralow+ onwards Cap reasonable in specific patients .. sac- TMT data will be interesting as usual vexing questions about sequencing..	Neutral	498
Ankur Mehta @oncomd	Capecitabine works well in first line for many in ‘non visceral crisis’ progression, post endocrine therapy. In Tropics 2 where Saci G has OS benefit, 92% received non capecitabine chemo.	Neutral	81

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Regulatory

TRODELVY® — FDA status

FDA APPROVEDTRODELVY® (sacituzumab govitecan-hziy) is an FDA-approved Trop-2 antibody-drug conjugate with multiple metastatic breast-cancer indications. For the full, current list of FDA indications and prescribing information, see trodelvy.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

TRODELVY® sentiment — FAQ

ASCENT-03

What do oncologists think of the ASCENT-03 trial (TRODELVY®)?

Across 26 verified physician voices in KOL Pulse's index for ASCENT-03, 23% expressed positive sentiment, 8% were nuanced (praising the result while flagging a caveat), 69% were neutral, and 0% were critical. Positive voices highlight the progression-free-survival benefit of single-agent sacituzumab govitecan over chemotherapy in first-line PD-(L)1-ineligible metastatic TNBC; nuanced and critical voices flag overall-survival maturity and how it sequences against other Trop-2 and HER2-directed ADCs.

Where can I find the ASCENT-03 trial data for TRODELVY® (sacituzumab govitecan)?

ASCENT-03 is registered as NCT05382299 and studied TRODELVY® (sacituzumab govitecan) in 1L metastatic TNBC, not candidates for PD-(L)1 inhibitors (monotherapy). For the full ASCENT-03 trial data and conference coverage, see the KOL Pulse ASCENT-03 trial profile at kolpulse.com/kol-pulse-trial-profile-ascent03.

ASCENT-04

What do oncologists think of the ASCENT-04 trial (TRODELVY®)?

Across 45 verified physician voices in KOL Pulse's index for ASCENT-04, 36% expressed positive sentiment, 15% were nuanced (praising the result while flagging a caveat), 42% were neutral, and 7% were critical. Positive voices highlight the progression-free-survival benefit of adding sacituzumab govitecan to pembrolizumab in first-line PD-L1-positive (CPS ≥ 10) metastatic TNBC; nuanced and critical voices flag the toxicity of the ADC + immunotherapy combination and whether benefit extends beyond the PD-L1-high population.

Where can I find the ASCENT-04 trial data for TRODELVY® (sacituzumab govitecan)?

ASCENT-04 is registered as NCT05382286 and studied TRODELVY® (sacituzumab govitecan) in 1L PD-L1-positive (CPS ≥ 10) metastatic TNBC (with pembrolizumab). For the full ASCENT-04 trial data and conference coverage, see the KOL Pulse ASCENT-04 trial profile at kolpulse.com/kol-pulse-trial-profile-ascent04.

SACI-IO HR+

What do oncologists think of the SACI-IO HR+ trial (TRODELVY®)?

Across 15 verified physician voices in KOL Pulse's index for SACI-IO HR+, 20% expressed positive sentiment, 40% were nuanced (praising the result while flagging a caveat), 27% were neutral, and 13% were critical. Positive voices highlight the exploratory signal for adding pembrolizumab to sacituzumab govitecan, particularly in PD-L1-positive HR+/HER2- disease; nuanced and critical voices flag the investigational combination did not reach statistical significance for PFS in the overall population (ESMO Breast 2026 final analysis).

Where can I find the SACI-IO HR+ trial data for TRODELVY® (sacituzumab govitecan)?

SACI-IO HR+ is registered as NCT04448886 and studied TRODELVY® (sacituzumab govitecan) in HR+/HER2- metastatic breast cancer (SG ± pembrolizumab) — INVESTIGATIONAL. For the full SACI-IO HR+ trial data and conference coverage, see the KOL Pulse SACI-IO HR+ trial profile at kolpulse.com/kol-pulse-trial-profile-saciio.

ASCENT-07

What do oncologists think of the ASCENT-07 trial (TRODELVY®)?

Across 14 verified physician voices in KOL Pulse's index for ASCENT-07, 0% expressed positive sentiment, 7% were nuanced (praising the result while flagging a caveat), 57% were neutral, and 36% were critical. Positive voices highlight a possible overall-survival trend and the preserved later-line role of sacituzumab govitecan (per TROPiCS-02); nuanced and critical voices flag sacituzumab govitecan did not improve progression-free survival versus chemotherapy in this first-line HR+/HER2- setting — ASCENT-07 did not meet its primary endpoint.

Where can I find the ASCENT-07 trial data for TRODELVY® (sacituzumab govitecan)?

ASCENT-07 is registered as NCT05840211 and studied TRODELVY® (sacituzumab govitecan) in 1L chemo in HR+/HER2- MBC after endocrine therapy — INVESTIGATIONAL (did not meet primary endpoint). KOL Pulse's ASCENT-07 trial profile is coming soon.

Regulatory

Is TRODELVY® (sacituzumab govitecan) FDA approved?

TRODELVY® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.